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For several decades the incidence of cutaneous malignant melanoma (CMM) steadily increased in fair-skinned,
indoor-working people around the world. Scientists think poor tanning ability resulting in sunburns initiate CMM, but
they do not understand why the incidence continues to increase despite the increased use of sunscreens and
formulations offering more protection. This paradox, along with lower incidences of CMM in outdoor workers, although
they have signiﬁcantly higher annual UV doses than indoor workers have, perplexes scientists. We found a temporal
exponential increase in the CMM incidence indicating second-order reaction kinetics revealing the existence of 2 major
risk factors. From epidemiology studies, we know one major risk factor for getting CMM is poor tanning ability and we
now propose the other major risk factor may be the Human Papilloma Virus (HPV) because clinicians ﬁnd b HPVs in
over half the biopsies. Moreover, we uncovered yet another paradox; the increasing CMM incidences signiﬁcantly
correlate with decreasing personal annual UV dose, a proxy for low vitamin D3 levels. We also discovered the incidence
of CMM signiﬁcantly increased with decreasing personal annual UV dose from 1960, when it was almost insigniﬁcant, to
2000. UV and other DNA-damaging agents can activate viruses, and UV-induced cytokines can hide HPV from immune
surveillance, which may explain why CMM also occurs in anatomical locations where the sun does not shine. Thus, we
propose the 2 major risk factors for getting CMM are intermittent UV exposures that result in low cutaneous levels of
vitamin D3 and possibly viral infection.
Introduction
For several decades the incidence of cutaneous malignant mel-
anoma (CMM) has steadily increased in fair-skinned, indoor-
working people around the world.1-10 Scientists are not sure why
CMM has steadily increased over time but from epidemiology
studies, we know that the numbers of benign naevi, light skin
and hair, and poor tanning ability are involved in the etiology.11
We can find clues as to what may contribute toward CMM in
the paradox between indoor and outdoor worker’s CMM inci-
dences and their personal annual UV (290–400 nm) doses. Out-
door workers get 3–10 times the annual UV dose that indoor
workers get,12 yet they have lower incidences of CMM and have
half the odds ratio (OR of about 0.8) that indoor workers have
(about 1.6) for getting CMM.13-16 From this data, one can con-
clude that something other than cumulative UV dose is primarily
involved in the etiology of CMM.
Most scientists believe intermittent UV exposures resulting in
sunburns initiate CMM,14 but the creation and use of sunscreens
did not reduce the incidence. Sunscreens with primarily UVB
(290–315 nm) protection were available from the early 1950s until
1988, and sunscreens with both UVB and UVA (316–400 nm)
protection were available since 1988 with increasing SPF numbers
over the years (http://en.wikipedia.org/wiki/Sunscreen). Some
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scientists think strong UVA exposures allowed by older sun-
screen formulations can also initiate CMM17 with unique signa-
ture mutations,18 while others believe the UVA passing through
the glass of office10 and car windows19 promotes it. We now
know that UVA can possibly also cause both initiation and pro-
motion of CMM because like UVB it causes similar DNA dam-
age, i.e., cyclobutane pyrimidine dimers.20 Additionally, UVA
causes oxidation of DNA bases in the cytosol prior to incorpo-
ration into the genomic DNA by polymerase eta21,22 and causes
DNA adduct formation in the presence of photosensitizers23
that people can ingest from common foods.24 Sunburns proba-
bly are not involved in the initiation or propagation of mela-
noma because a melanoma study using the opossum animal
model, Monodelphis domestica, ironically showed intense sun-
burn doses of UVB gave significantly fewer melanomas than
sub-erythemal doses.25 UVB exposures of skin creates cutaneous
vitamin D3 production
26 that sunscreens dramatically reduce.27
Furthermore, contrary to popular belief, outdoor workers get
numerous sunburns28–31 reviewed by Glanz.32
The major risk factors involved in CMM had to exist prior to
the first documented increase in the incidence in 1936 (Connect-
icut, United States).33 To understand how many major risk fac-
tors are responsible for the increasing incidence of CMM, we
must know the temporal incidences as far back as possible to dis-
cern if the increase is linear (one major risk factor) or exponential
(interaction between 2 major risk factors). For this reason, we
analyzed the fair-skinned European countries’ CMM incidences
over time and personal annual UV dose for males and females
from 1955 to 2000 using data from the International Agency for
Research on Cancer (IARC). We found an exponential increase
in the incidence of CMM, implicating 2 major risk factors. In
addition, we found CMM increases with decreasing personal UV
dose, implicating low cutaneous vitamin D3 levels as one of the
major risk factors. We suggest the other major risk factor, besides
the germline incorporated Human Endogenous Retrovirus
(HERV) that is already implicated in the etiology of CMM and
other cancers,34 may be HPV infection because clinicians found
it in over half the CMM’s biopsied.35-38
Materials and Methods
Temporal analysis
We analyzed the CMM incidences at 5-year interval mid-
points from 1955 to 2000 for European countries using IARC’s
age-adjusted, world population normalized data.1–9 We aggre-
gated the regional registries for England, Germany, Poland,
France, and Switzerland to estimate national incidence trends.
The temporal CMM data plotted in Figure 1 for all Euro-
pean countries was from the averaged data in Table 1A and the
western (<17 E) and eastern (>17E) countries were plotted
from the averaged data in Tables 1B and1C, respectively.
Because we wanted to compare the European CMM incidences
of white people (skin types I and II),39 we excluded countries
that had populations with primarily skin types III or darker
(e.g., Italy, Spain, and Portugal). To show a lack of bias, we
also analyzed the data of all the countries listed inTable 1A and
included Italy, Spain, and Portugal and found a similar expo-
nential increase in the CMM incidences with a slightly reduced
slope (results not shown). The temporal data in Figure 2 was
plotted from the averaged data in Table 2 for countries located
every 5N from 46–50N, 51–55N, 56–60N to over 60N.
In Figure 3, we compare female and males in the northern
(averaged 46–55N for »50N) and southern (averaged all
countries above 55N for »60N) regions of Europe from the
averaged data in Table 3. In some of our analyses (Fig. 2
Figure 1. Temporal CMM incidences among fair-skinned people in
Europe (plotted from the averaged data in Table 1A), western Europe
<17E (Table 1B), and eastern Europe >17E (Table 1C). Note the expo-
nential increase in CMM over the decades (semi-log plot). See statistical
data in Table 5A.
Table 1A. European countries with CMM incidence data (24 countries aver-
aged in Fig. 1).
All Europe N 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000
Romania 46 0.60 1.45 2.90 1.40 2.20
Slovenia 46 1.35 1.85 2.35 1.95 2.55 3.80 5.05 6.80 8.85
Switzerland 47 4.89 6.85 8.83 10.30 12.10 15.21
France 47 2.53 3.32 4.07 5.31 7.23 8.41
Hungary 48 1.85 1.73 2.30 2.73 3.60
Austria 48 14.00 10.90 11.02
Slovakia 49 2.50 3.70 3.80 4.40 5.05 6.35
Czech 50 5.45 6.30 8.00 9.35
Poland 51 1.30 1.55 1.90 2.34 2.49 3.24 3.91 4.67
Germany 51 2.00 2.20 2.25 3.83 4.45 5.55 6.20 8.77
Belgium 51 5.23 6.2
Netherlands 52 1.70 2.54 4.95 5.03 7.62 9.48 11.12
England 52 1.44 1.67 1.90 2.27 3.15 4.37 6.11 7.13 8.45
Ireland 53 4.50 6.30 8.55 8.50 9.20
Belarus 54 1.80 2.10 2.50 3.10
Lithuania 55 2.55 3.3 4.45
Denmark 56 1.9 2.7 3.9 5.4 7.15 8.75 10.3 12 13
Scotland 57 1.5 2.45 3 3.74 5.77 7.03 8.5 9.25
Latvia 57 2.45 2.55 3.35 3.7
Estonia 59 2.9 3.85 4.55 5.95
Sweden 62 2.60 3.20 4.50 5.45 7.70 9.55 11.05 11.85 12.00
Iceland 63 1.25 2.60 3.85 4.55 5.45 8.65 14.15
Norway 64 1.99 2.65 3.80 5.55 8.30 9.70 12.00 14.70 15.20 14.40
Finland 65 1.55 2.00 2.20 2.85 3.85 4.80 6.30 7.25 7.35 8.15
Average 53 1.81 1.96 2.17 2.88 3.33 4.48 5.16 6.82 7.62 8.9
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and 3), we included a country only if it had more than 50% of
the 5-year averaged CMM incidence data; countries excluded
were Austria, Czech, Belarus, Belgium, Estonia, Hungary, Ire-
land, Latvia, Lithuania, and Romania.
Personal annual UV dose analysis
Latitude is a proxy for personal annual UV doses. For popula-
tions living in the regions analyzed and plotted in Figure 4, the
average annual personal UV doses were calculated from the equa-
tion derived from the slope of the line (R2 D 0.99) from several
countries known population’s UV doses after geometric conver-
sion from planar to cylinder measurements, which represent the
human body.40 The countries that generated this equation with
average annual personal UV doses were Sweden (60N; 5,200 J/
m2), Denmark (55N; 6,800 J/m2), the Netherlands (52.5N;
7,000 J/m2), and the US (34N, 10,000 J/m2 and 44N, 12,000
J/m2):
UVdoseD ¡ 280X C 22000
where X is the population centered latitude.41 These average
annual personal UV doses are erythemally-weighted UV doses in
J/m2 that do not include vacations, which can be taken at any lat-
itude.12,42,43 Erythemally-weighted UV doses are obtained by
multiplying the solar spectra in W/m2, wavelength for wave-
length from 290–400 nm, by the erythemal action spectrum,44
and then multiplied by the number of seconds the person is
exposed to that source to get the UV dose in J/m.2,12
Population weighting and statistical analysis
For all the temporal data, we conducted linear regression anal-
ysis using Minitab 16.2.4 (Minitab Inc.., State College, Pennsyl-
vania) to evaluate the association between personal annual UV
doses (independent variable) and log(CMM) incidence rate
(dependent variable). We then performed multiple linear regres-
sions to simultaneously assess the role of time and latitude in pre-
dicting log(CMM) incidence rate (Table 5A).
Table 1B.Western European countries<17E with CMM incidence data (15 countries averaged in Fig. 1).
West Europe <17E N 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000
Slovenia 46 1.35 1.85 2.35 1.95 2.55 3.80 5.05 6.80 8.85
Switzerland 47 4.89 6.85 8.83 10.30 12.10 15.21
France 47 2.53 3.32 4.07 5.31 7.23 8.41
Austria 48 14.00 10.90 11.02
Czech 50 5.45 6.30 8.00 9.35
Germany 51 2.00 2.20 2.25 3.83 4.45 5.55 6.20 8.77
Belgium 51 5.225 6.2
Netherlands 52 1.70 2.54 4.95 5.03 7.62 9.48 11.12
England 52 1.44 1.67 1.90 2.27 3.15 4.37 6.11 7.13 8.45
Ireland 53 4.50 6.30 8.55 8.50 9.20
Denmark 56 1.9 2.7 3.9 5.4 7.15 8.75 10.3 11.95 13
Scotland 57 1.5 2.45 3 3.74 5.77 7.03 8.5 9.25
Sweden 62 2.60 3.20 4.50 5.45 7.70 9.55 11.05 11.85 12.00
Iceland 63 1.25 2.60 3.85 4.55 5.45 8.65 14.15
Norway 64 1.99 2.65 3.80 5.55 8.30 9.70 12.00 14.70 15.20 14.40
Average 53 1.95 1.96 2.56 3.37 3.69 5.11 6.38 8.38 9.18 10.62
Table 1C. Eastern European countries >17E with CMM incidence data (9
countries averaged in Fig. 1).
East Europe N 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000
>17E
Romania 46 0.60 1.45 2.90 1.40 2.20
Slovakia 49 2.50 3.70 3.80 4.40 5.05 6.35
Hungary 48 1.85 1.73 2.30 2.73 3.60
Poland 51 1.30 1.55 1.90 2.34 2.49 3.24 3.91 4.67
Belarus 54 1.80 2.10 2.50 3.10
Lithuania 55 2.55 3.3 4.45
Latvia 57 2.45 2.55 3.35 3.7
Estonia 59 2.9 3.85 4.55 5.95
Finland 65 1.55 2.00 2.20 2.85 3.85 4.80 6.30 7.25 7.35 8.15
Average 54 1.55 2.00 1.49 1.89 2.69 2.99 3.19 3.71 4.29 5.20
Figure 2. Temporal CMM incidences among fair-skinned people in
Europe averaged every 5N for only the European countries with more
than 50% complete data sets; northern most (>60N; mean »64N),
northern (»51–55N; mean »52N), middle (56–60N; »57N), and
southern Europe (»46–50N; mean »48N) plotted from the averaged
data in Table 2.
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Using Minitab 16.2.4 (Penn State, State College, Pennsylvania,
US), we performed weighted regression of the cancer incidences
on the different personal annual UV doses in the European coun-
tries by population (Table 5B).45
Results
We wanted to know how fast CMM is increasing in the white
populations over time and how CMM correlates with personal
annual UV dose in Europe.
First, we asked how the CMM incidences changed over time
in all of Europe. Figure 1 shows that CMM has been exponen-
tially increasing over the decades in all of Europe (Table 1A). It
also shows the western European countries (Table 1B) have a
consistently higher incidence than the eastern European countries
(Table 1C).
Next we asked how the southern (46–50N), middle
(51–55N), northern (56–60N), and northernmost (>60N)
European countries’ CMM incidences changed over time to learn
if the increase is linear or exponential in every latitudinal region.
We only included countries with more than 50% of the available
data (Table 2) in Figure 2 so as not to skew the slopes of the
trendlines by data that was only collected in the later years.
We then asked how females and males CMM rates compare
in northern (»60N) and southern (»50N) Europe (Table 3).
Figure 3 shows females always have higher incidences of CMM
than males in both northern (»60N) and southern (»50N)
Europe and that both sexes have temporal exponential increases
in CMM.
Then we asked how the incidence of CMM varied with per-
sonal annual UV dose, starting at 1960 and assessing every
20 years, to see if CMM correlated with increasing or decreasing
latitude. Figure 4 shows all the countries with available data in
1960 that we followed every 20 y (Table 4). In 1980 and 2000,
the CMM incidence significantly increased with decreasing per-
sonal annual UV dose.
Table 2. Only European countries with more than 50% CMM incidence data
averaged every 5N (Figure 2).
46–50N N 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000
Slovenia 46 1.35 1.85 2.35 1.95 2.55 3.80 5.05 6.80 8.85
Switzerland 47 4.89 6.85 8.83 10.30 12.10 15.21
France 47 2.53 3.32 4.07 5.31 7.23 8.41
Slovakia 49 2.50 3.70 3.80 4.40 5.05 6.35
Average 47 1.35 1.85 2.35 2.97 4.10 5.12 6.27 7.80 9.70
51–55N N 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000
Poland 51 1.30 1.55 1.90 2.34 2.49 3.24 3.91 4.67
Germany 51 2.00 2.20 2.25 3.83 4.45 5.55 6.20 8.77
Netherlands 52 1.70 2.54 4.95 5.03 7.62 9.48 11.12
England 52 1.44 1.67 1.90 2.27 3.15 4.37 6.11 7.13 8.45
Average 52 1.57 1.66 1.88 2.24 3.57 4.08 5.63 6.68 8.25
56–60N N 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000
Denmark 56 1.9 2.7 3.9 5.4 7.15 8.75 10.3 12 13
Scotland 57 1.5 2.45 3 3.74 5.77 7.03 8.5 9.25
Average 57 1.90 2.70 2.70 3.93 3.00 5.44 7.26 8.64 10.23 11.13
>60N N 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000
Sweden 62 2.60 3.20 4.50 5.45 7.70 9.55 11.05 11.85 12.00
Iceland 63 1.25 2.60 3.85 4.55 5.45 8.65 14.15
Norway 64 1.99 2.65 3.80 5.55 8.30 9.70 12.00 14.70 15.20 14.40
Finland 65 1.55 2.00 2.20 2.85 3.85 4.80 6.30 7.25 7.35 8.15
Average 64 1.77 2.13 3.07 3.88 5.87 6.51 8.10 9.61 10.76 12.18
Figure 3. Temporal comparison of female and male CMM rates in north-
ern (>55 N; mean »60N) and southern (46–55N; mean »50N)
Europe (Table 3; statistical data in Table 5B).
Table 3. Males compared with females in northern (»60N) and southern
(»50N) Europe.
Europe N 1960 1965 1970 1975 1980 1985 1990 1995 2000
Europe Female »60 2.71 3.24 4.40 4.89 6.86 7.19 8.39 9.74 11.03
Europe Male »60 2.11 2.53 3.40 3.98 5.10 5.88 7.14 8.11 9.13
Europe Female »50 1.68 1.75 2.09 2.70 4.29 4.84 7.03 7.54 8.88
Europe Male »50 1.25 1.34 1.63 2.38 2.89 3.77 5.63 6.59 7.98
Figure 4. Average personal annual UV dose for populations of each
country and CMM incidence trends in Europe over time. Eight European
countries that had CMM incidence data in 1960 were followed every 20
y (Table 4; Table 5A).
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Because we found CMM incidence increases with decreasing UV
dose in Europe, we plotted out Robinson et al.’s (1998) UVB-
dose response data25 for the marsupial animal model because the
data was obtained in a controlled experimental environment
(e.g., food intake and light/dark cycles, etc.). Figure 5 shows the
percentage of animals having CMM actually decreased with
increasing UVB doses, including those producing sunburns, in a
dose-dependent linear fashion (R2 D 0.96).
Finally, we asked if our European CMM observations were
significant or not. Table 5A shows that the significance of the
exponential increase in CMM over time (p < 10–30) and decreas-
ing with UV dose (p < 2.0 £ 10–7) have truly remarkably small
P values.Table 5B shows that both females and males in northern
(»60N) and southern (»50N) Europe have significantly lower
CMM incidences with higher UV dose (p < 10¡6).
Discussion
We analyzed the CMM incidences in Europe to know
how the rate increased over time and how it correlated with
personal annual UV dose, which is a proxy for vitamin D sta-
tus. We found the incidence of CMM increased at an expo-
nential rate in Europe over time (Fig. 1; Table 1A and 5A)
with the western European countries having higher rates
(Table 1B) than the eastern European countries (Table 1C),
possibly due to cultural differences (e.g., more time indoors)
or over diagnosis. However, because this exponential increase
over time is seen in both western and eastern Europe it is
unlikely to be from over diagnosis, as suggested by some sci-
entists, because it is not possible to increasingly over diagnose
at an increasing rate to that extent for more than 5 decades
(P < 10–7). Exponential increases occur every 5N in Europe
(Fig. 2;Table 2), which shows the increase is not specific to
any particular latitudinal region. In addition, CMM is
significantly higher for females than for males in both north-
ern (»60N) and southern Europe (»50N;Figure 3,Table 3
and 5B). Counterintuitively, the increasing incidences of
CMM significantly correlate with decreasing personal annual
UV dose, a proxy for decreasing personal vitamin D3, which
is most notable after 1960 when it was not significant
(Fig. 4; Table 4). The significant increasing slope in the inci-
dence of CMM with decreasing UV dose over time, espe-
cially from 1980 to 2000, reveals that the gradation of
lighter skin color with increasing latitude in Europe is not a
reasonable explanation because it remained fairly constant.
Furthermore, although the ratio of UVA to UVB increases
with increasing latitude, which affects mortality of CMM,46
this is not a reasonable explanation for temporal incidence
increases from 1960 to 2000 because the ratio of UVA to
UVB does not change very much over time. Finally, some
investigators have suggested that increasing people’s skin sur-
face area from wearing smaller bathing suits over time is
responsible, but this is also not a reasonable explanation
because people did not expose more skin in an exponential
fashion over time. Moreover, exposing more skin only
increases the UV dose to those areas of the body, which is
irrelevant because CMM also occurs where the sun does not
shine. Instead, the temporal exponential increase shows sec-
ond order reaction kinetics in the CMM incidence rates
(Fig. 1 and 2), which reveals 2 major risk factors and sug-
gests an infectious agent or agents are involved in the
etiology.
Table 4. CMM incidences in 8 countries that had data in 1960 were followed
every 20 y
Europe N UV Dose 1960 1980 2000
Slovenia 46 9200 1.35 2.55 8.85
Netherlands 52 7500 1.70 4.95 11.12
England 52 7500 1.44 3.15 8.45
Denmark 56 6400 2.70 7.15 13.00
Sweden 62 4700 2.60 7.70 12.00
Iceland 63 4400 1.25 3.85 14.15
Norway 64 4100 2.65 9.70 14.40
Finland 65 3800 2.00 4.80 8.15
Table 5A. Statistics for multiple linear regression of log(CMM incidence)
data versus time and UV dose in all of Europe (N D 151).
Predictor Coefﬁcient T P
Year 0.02 20 < 10–30
UV Dose ¡0.000055 ¡5.4 <2.0 £ 10–7
Table 5B. Statistics for females and males in northern and southern Europe
Europe Slope R2 P
Europe Female (»60N) 0.035 0.98 2.7 x 10–7
Europe Male (»60N) 0.016 0.99 3.1 x 10–8
Europe Female (»50N) 0.020 0.97 4.2 X 10–7
Europe Male (»50N) 0.022 0.99 3.5 x 10–8
Figure 5. Percentage of animals with CMM decreases with increasing
UVB dose in a linear dose-dependent manner (R2 D 0.96). Plotted from
the data of Robinson et al.25
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From epidemiology studies, we know one major risk factor for
indoor workers‘ getting CMM is intermittent UV exposures that
were believed to involve sunburn episodes based on long-term
memory recall surveys.47 Scientists believed outdoor workers did
not get sunburns, especially blistering sunburns, like indoor
workers get because outdoor workers were found to have lower
incidences of CMM and half the odds ratio (about 0.8) that
indoor workers have for getting it (about 1.6).13-16 This belief
arose because outdoor workers are exposed to UV every day,
unlike indoor workers, so that their skin acclimates by thickening
the stratum corneum and by producing the pigment melanin
(tan). However, contrary to this popular belief, outdoor workers
can get numerous sunburns and can also experience blistering
events28–31 reviewed by Glanz.32 For example, the study by Bul-
ler et al.30 found 45% of the ski area employees got sunburned
and 8% received blistering sunburns. Another study measured
alpine skiers who got 0.5–7.6 times the minimum erythemal
dose (MED), or the minimum amount of UV dose needed to
produce a mild sunburn, for white individuals with skin type II
and 10% got more than 1 MED/h during peak exposure times.48
Furthermore, Robinson et al.25 found that sunburn doses of
UVB yielded fewer animals with melanoma than suberythemal
UVB doses (175 J/m2), which yielded the greatest percentage of
opossums with melanomas. In fact, the percentage of animals
with melanomas decreased with increasing UVB dose in a linear
dose-dependent manner (see Fig. 5, R2 D 0.96). However, the
decisive factor was published by Vainio et al.49 concerning an
official IARC report that declared sunscreens significantly reduce
the incidence of sunburns but that they do not reduce the OR
for getting melanoma below 1.0 like outdoor workers’ continual
UV exposures do (OR»0.8), as shown by multiple independent
studies.13-16 So how can sunburns be responsible for initiating
melanoma?
Rather than sunburns, we propose that intermittent UV expo-
sures result in low levels of cutaneous vitamin D3 because only
UVB radiation can make vitamin D3
26 and UVB decreases with
increasing latitude12 while the incidence of CMM increases with
increasing latitude (Fig. 4; Table 5A). Because outdoor workers
are chronically exposed to noontime UVB radiation (»11 a.m.
to 3 pm), they make plenty of vitamin D3 in their skin and have
healthy blood levels. In contrast, indoor workers get intermit-
tently exposed to UVB radiation (weekends and vacations) so
that they do not have high levels of vitamin D3 in their skin or
blood. Outdoor workers (gardeners) who get about 5 times the
solar UV dose that indoor workers get have about twice the vita-
min D blood levels that indoor workers have.50 Additionally,
indoor workers get exposed to only UVA radiation that passes
through glass windows while they work in their offices10 and
drive in their cars.19 UVA cannot make vitamin D3
26 but rather
breaks it down in the skin, capillaries, and when bound to the
vitamin D-binding protein.51 Recently, the UVA passing
through airplane windows has been implicated as the cause for
pilots and flight attendants having twice the incidence of CMM
as the general population.52
Vitamin D3 is important in the etiology of CMM because
melanoma cells can convert it to the hormone, 1,25
dihydroxyvitamin D3, or calcitriol,
53 and initiate an apoptotic
cell death mechanism54 via the nuclear vitamin D receptor
(VDR).55 We can find evidence of vitamin D-induced suicidal
death of melanoma cells from VDR polymorphisms that result
in an increased risk for CMM, reviewed by Denzer et al.56 and
decreased survival of patients.57 Moreover, melanoma patients,
who get regular, moderate sun exposures live longer than those
who do not58 and CMM patients were found to have deficient
vitamin D levels when compared with patients who did not have
CMM.59 Furthermore, calcitriol controls the growth of mela-
noma cells,60-62 inhibits tumor promotion63 and angiogenesis,64
and boosts the immune system.65–67 Recently, the importance of
vitamin D in T cell activation has been revealed; they cannot kill
virally infected cells or cancer cells unless they have enough vita-
min D.65
Other than our data suggesting low vitamin D3 levels as one
of 2 major risk factors for getting CMM, we believe the other
major risk factor is HPV infection. Although we do not present
any data to support our belief, we think HPV is involved because
HPV-38 is found in over half the CMM biopsies35–38 and HPV
infection is increasing at an exponential rate in Europe.68 Clini-
cians found different strains of type b HPV, primarily HPV-38
and 16/18, in CMM and they found other strains of HPV, pri-
marily HPV-77, in non-melanoma skin cancers.69 The presence
of HPV shortens the latency period of squamous cell carcinoma
from »15–20 y to »2–5 y69 and it might also shorten the
latency period of CMM, which could explain why clinicians
observe a seasonal diagnostic pattern.70–72 HPV incorporates
into the host’s genomic DNA during the DNA damage repair
processes73–75 and once incorporated deploys its carcinogenic
regime of E6 and E7 proteins that inactivate p5376 and Bak,77
respectively, so that the cell cannot die via either the DNA-dam-
age or receptor-initiated apoptotic pathways.78 However, vitamin
D3/calcitriol can initiate a p53-independent apoptotic cell death
pathway79 circumventing HPV’s plan for cellular immortaliza-
tion80 by destroying the infected cell. Note that one of HPV’s
survival strategies is the production of E2 protein that causes the
infected cell to release IL-1081 helping to conceal HPV from
immune surveillance.82 Moreover, the opossums that got mela-
nomas in the Robinson et al. 1998 study25 were infected with
PV, as demonstrated by UVB-induced papillomas.83 In addition,
it now appears that HPV can establish a latent infection84 that
may also have consequence both in the UV interaction and in
the disruption of normal skin, which has been implicated in mel-
anoma.85 HPV may represent the first step in the transformation
process because it’s E6 and E7 proteins immortalize the melano-
cyte80 setting it up for accumulating DNA mutations over time
and possibly activating HERV, as other viruses are known to do.
Herein we present plausible explanations for the paradoxes
observed over the decades from the second order reaction kinetics
that reveals the existence of 2 major risk factors in the etiology of
CMM. From epidemiology studies, we know intermittent UV
exposures are a risk factor for getting CMM; we propose low
cutaneous levels of vitamin D3, rather than sunburns are a risk
factor for getting CMM and we suggest the other major risk fac-
tor, along with HERV, may be HPV infection.
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